# PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer

> **NCT05303714** · PHASE3 · RECRUITING · sponsor: **Azienda Ospedaliera Universitaria Integrata Verona** · enrollment: 98 (estimated)

## Conditions studied

- Oligometastatic Gastric Adenocarcinoma

## Interventions

- **COMBINATION_PRODUCT:** FOLFOX and PIPAC

## Key facts

- **NCT ID:** NCT05303714
- **Lead sponsor:** Azienda Ospedaliera Universitaria Integrata Verona
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-31
- **Primary completion:** 2025-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05303714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05303714, "PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT05303714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*